Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702

Volume: 20, Issue: 11, Pages: 1121 - 1122
Published: Aug 11, 2017
Abstract
The article by Thibault et al.1 establishes the superiority of daclatasvir-sofosbuvir (DCV + SOF) over sofosbuvir-ribavirin (SOF + RBV) in the treatment of genotype 3 chronic hepatitis C infection...
Paper Details
Title
Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702
Published Date
Aug 11, 2017
Volume
20
Issue
11
Pages
1121 - 1122
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.